NO20044903L - Anvendelse av nye etonogestrel estere - Google Patents

Anvendelse av nye etonogestrel estere

Info

Publication number: NO20044903L
Authority: NO; Norway
Prior art keywords: new; etonogestrel esters; contraceptive; esters; new etonogestrel
Prior art date: 2002-05-30

Application number

NO20044903A

Other languages

English (en)

Norwegian (no)

Inventor

Hendrikus Adrianus Anton Voort

Dirk Leysen

Arij Jan Grootenhuis

Henrik De Nijs

Jaap Van Der Louw

Original Assignee

Akzo Nobel Nv

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-05-30

Filing date

2004-11-10

Publication date

2005-02-25

2004-11-10 Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv

2005-02-25 Publication of NO20044903L publication Critical patent/NO20044903L/no

Links

GCKFUYQCUCGESZ-BPIQYHPVSA-N etonogestrel Chemical class O=C1CC[C@@H]2[C@H]3C(=C)C[C@](CC)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 GCKFUYQCUCGESZ-BPIQYHPVSA-N 0.000 title 1
239000003433 contraceptive agent Substances 0.000 abstract 2
230000002254 contraceptive effect Effects 0.000 abstract 2
229960002941 etonogestrel Drugs 0.000 abstract 1
-1 etonogestrel ester Chemical class 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Gynecology & Obstetrics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Psychiatry (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Hospice & Palliative Care (AREA)
Pregnancy & Childbirth (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)

NO20044903A 2002-05-30 2004-11-10 Anvendelse av nye etonogestrel estere NO20044903L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP02077118		2002-05-30
PCT/EP2003/050188 WO2003101374A2 (en)	2002-05-30	2003-05-22	Use of new etonogestrel esters

Publications (1)

Publication Number	Publication Date
NO20044903L true NO20044903L (no)	2005-02-25

Family

ID=29595013

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20044903A NO20044903L (no)	2002-05-30	2004-11-10	Anvendelse av nye etonogestrel estere

Country Status (26)

Country	Link
US (1)	US20050222114A1 (is)
EP (1)	EP1513588B1 (is)
JP (1)	JP2005532336A (is)
KR (1)	KR20050005507A (is)
CN (1)	CN1655848A (is)
AR (1)	AR040129A1 (is)
AT (1)	ATE394140T1 (is)
AU (1)	AU2003246740B2 (is)
BR (1)	BR0311248A (is)
CA (1)	CA2487293A1 (is)
DE (1)	DE60320786D1 (is)
ES (1)	ES2305498T3 (is)
HR (1)	HRP20041127A2 (is)
IL (1)	IL165125A0 (is)
IS (1)	IS7537A (is)
MX (1)	MXPA04011798A (is)
NO (1)	NO20044903L (is)
NZ (1)	NZ536618A (is)
PE (1)	PE20040042A1 (is)
PL (1)	PL373295A1 (is)
RS (1)	RS101004A (is)
RU (1)	RU2322986C2 (is)
TW (1)	TW200400041A (is)
UA (1)	UA80703C2 (is)
WO (1)	WO2003101374A2 (is)
ZA (1)	ZA200409498B (is)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW200403065A (en) *	2002-05-30	2004-03-01	Akzo Nobel Nv	New etonogestrel esters
US20130123523A1 (en) *	2011-11-10	2013-05-16	Klaus Nickisch	Methods for the preparation of etonogestrel and desogestrel
DE102012211511A1 (de) *	2012-07-03	2014-01-09	Siemens Aktiengesellschaft	Bestimmung der Eignung einer Ressource
US10624903B2 (en) *	2017-10-19	2020-04-21	Evestra, Inc.	Longer-acting progestin prodrug contraceptives
CN111057120B (zh) *	2019-12-27	2021-04-27	苏州翔实医药发展有限公司	一种依托孕烯衍生物a及其制备方法和用途
US20230227492A1 (en) *	2020-06-11	2023-07-20	The Usa As Represented By The Secretary, Department Of Health And Human Services	Monomeric and oligomeric compound embodiments as contraceptives and therapies and methods of making and using the same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4227989A1 (de) *	1992-08-21	1994-06-09	Schering Ag	Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4240806A1 (de) *	1992-12-01	1994-06-09	Schering Ag	Mittel zur transdermalen Applikation enthaltend 14alpha,17alpha-Ethanoestra-1,3,5(10)-trien-3,17beta-diol
JPH07101884A (ja) *	1993-10-01	1995-04-18	Sanei Gen F F I Inc	水溶性ヘミセルロースを含有する製剤
HUT75159A (en) *	1993-12-27	1997-04-28	Akzo Nobel Nv	Percutaneously absorbable preparation, containing 3-ketodesogestrel and 17 beta-estradiol
EP0848620A1 (de) *	1995-07-17	1998-06-24	Schering Aktiengesellschaft	Mittel zur transdermalen applikation enthaltend ester des 3-ketodegestrel
WO1999067270A1 (en) *	1998-06-19	1999-12-29	Akzo Nobel N.V.	Cycloalkyl-carboxylic acid esters of 7.alpha.methyl-estr-4-en-3-one 17.beta.-ol (19-nor 7.alpha.-methyltestosterone)
NZ508299A (en) *	1998-06-19	2003-04-29	Akzo Nobel Nv	Testosterone derivative
US6180682B1 (en) *	1999-01-26	2001-01-30	Virgil A. Place	Buccal drug delivery system for use in male contraception
TW200403065A (en) *	2002-05-30	2004-03-01	Akzo Nobel Nv	New etonogestrel esters

2003
- 2003-05-19 TW TW092113492A patent/TW200400041A/zh unknown
- 2003-05-22 BR BR0311248-9A patent/BR0311248A/pt not_active IP Right Cessation
- 2003-05-22 RU RU2004138809/15A patent/RU2322986C2/ru active
- 2003-05-22 NZ NZ536618A patent/NZ536618A/en unknown
- 2003-05-22 EP EP03755980A patent/EP1513588B1/en not_active Expired - Lifetime
- 2003-05-22 AU AU2003246740A patent/AU2003246740B2/en not_active Ceased
- 2003-05-22 US US10/517,362 patent/US20050222114A1/en not_active Abandoned
- 2003-05-22 PL PL03373295A patent/PL373295A1/xx not_active Application Discontinuation
- 2003-05-22 CN CNA038123657A patent/CN1655848A/zh active Pending
- 2003-05-22 CA CA002487293A patent/CA2487293A1/en not_active Abandoned
- 2003-05-22 MX MXPA04011798A patent/MXPA04011798A/es unknown
- 2003-05-22 DE DE60320786T patent/DE60320786D1/de not_active Expired - Fee Related
- 2003-05-22 AT AT03755980T patent/ATE394140T1/de not_active IP Right Cessation
- 2003-05-22 UA UA20041109285A patent/UA80703C2/uk unknown
- 2003-05-22 KR KR10-2004-7019327A patent/KR20050005507A/ko not_active Withdrawn
- 2003-05-22 JP JP2004508732A patent/JP2005532336A/ja not_active Withdrawn
- 2003-05-22 ES ES03755980T patent/ES2305498T3/es not_active Expired - Lifetime
- 2003-05-22 RS YU101004A patent/RS101004A/sr unknown
- 2003-05-22 WO PCT/EP2003/050188 patent/WO2003101374A2/en not_active Ceased
- 2003-05-22 HR HR20041127A patent/HRP20041127A2/hr not_active Application Discontinuation
- 2003-05-26 PE PE2003000508A patent/PE20040042A1/es not_active Application Discontinuation
- 2003-05-28 AR ARP030101858A patent/AR040129A1/es unknown
2004
- 2004-11-09 IL IL16512504A patent/IL165125A0/xx unknown
- 2004-11-10 NO NO20044903A patent/NO20044903L/no not_active Application Discontinuation
- 2004-11-18 IS IS7537A patent/IS7537A/is unknown
- 2004-11-24 ZA ZA200409498A patent/ZA200409498B/xx unknown

Also Published As

Publication number	Publication date
ES2305498T3 (es)	2008-11-01
PE20040042A1 (es)	2004-01-31
WO2003101374A3 (en)	2004-02-26
RU2322986C2 (ru)	2008-04-27
IL165125A0 (en)	2005-12-18
AU2003246740B2 (en)	2009-01-08
EP1513588B1 (en)	2008-05-07
RU2004138809A (ru)	2005-06-10
AU2003246740A1 (en)	2003-12-19
DE60320786D1 (de)	2008-06-19
HK1072568A1 (en)	2005-09-02
CN1655848A (zh)	2005-08-17
PL373295A1 (en)	2005-08-22
US20050222114A1 (en)	2005-10-06
IS7537A (is)	2004-11-18
BR0311248A (pt)	2005-03-15
EP1513588A2 (en)	2005-03-16
NZ536618A (en)	2007-06-29
RS101004A (sr)	2006-10-27
CA2487293A1 (en)	2003-12-11
UA80703C2 (en)	2007-10-25
JP2005532336A (ja)	2005-10-27
ZA200409498B (en)	2006-05-31
TW200400041A (en)	2004-01-01
MXPA04011798A (es)	2005-03-31
KR20050005507A (ko)	2005-01-13
HRP20041127A2 (en)	2005-02-28
ATE394140T1 (de)	2008-05-15
WO2003101374A2 (en)	2003-12-11
AR040129A1 (es)	2005-03-16

Legal Events

Date	Code	Title	Description
2009-12-21	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
EP1512396A4 (en)	2008-12-31	HEMMER AGAINST ACTIVATION OF AP-1 AND NFAT
EE200400024A (et)	2004-06-15	Kolesterüülestri ülekandevalgu inhibiitorite iseemulgeeruvad formulatsioonid
DK1490463T3 (da)	2021-09-06	Lav-transfedtsyrer til konfekture og fedtsammensætninger til bagning
DE60029956D1 (de)	2006-09-21	Amid-substituierte Imidazochinoline
SE9802333D0 (sv)	1998-06-29	Novel combination
EP1246621A4 (en)	2004-11-24	NITROSED AND NITROSYLATED CYCLOOXYGENASE-2 INHIBITORS, COMPOSITIONS AND METHODS FOR THEIR USE
IS5976A (is)	2001-06-22	Bensóheteróhringir og notkun theirra sem MEK-hemlar
NO20022988L (no)	2002-08-21	Vedvarende frigivelse (med dybdevirkning) av syklooksygenase- 2-inhibitor
NO20041872L (no)	2004-05-06	Esterforbindelser og medisinsk anvendelse derav
NO20020770L (no)	2002-04-16	Anvendelse av monoaminoksidaseinhibitorer for fremstilling av legemidler egnet for behandling av obesitas
LU93072I2 (fr)	2016-07-12	Inhibiteur de la protéinase alpha-1 humaine
EE200100669A (et)	2003-02-17	Sulfoonamiid- ja sulfamiidasendatud imidasokinoliinid
NO20043506L (no)	2004-10-19	Kontrollert frigivende farmasoytiske doseringsformer av en kolesterylester overforingsproteininhibitor
CY1107641T1 (el)	2013-04-18	Φαρμακευτικη συνθεση περιλαμβανουσα αναστολεα λιπασης και μονο-εστερα λιπαρου οξεος με σακχαροζη
EP1569684A4 (en)	2006-08-02	USE OF HMGB FRAGMENTS AS ANTI-INFLAMMATORY AGENTS
NO20024528L (no)	2002-11-19	Proteaseinhibitor, farmasoytisk sammensetning og anvendelse av forbindelsen
CY2009001I1 (el)	2009-11-04	Νεα μορφη κρυσταλλου του παραγωγου πυρρολιδυλοθειοκαρβαπενεμης
ATE445389T1 (de)	2009-10-15	Liposomale glucocorticoide
IS7528A (is)	2004-11-15	Nýir etónógestrel esterar
DK0869965T3 (da)	2000-10-16	Steroidnitritesterderivater anvendelige som antiinflammatoriske lægemidler
NO20044903L (no)	2005-02-25	Anvendelse av nye etonogestrel estere
DE60317214D1 (de)	2007-12-13	Kristallines gamma-lacton der17beta-hydroxy-7alpha-(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carbonsäure
ES2176475T3 (es)	2002-12-01	Composiciones de inhibidor bowman-birk para el tratamiento de enferm edades inflamatorias.
NO20014444D0 (no)	2001-09-13	Topisk appliserbare bioadhesive preparater samt fremgangsmåter for anvendelse og fremstilling derav
NO20032054D0 (no)	2003-05-08	Fettsyreanaloger for behandling av inflammatoriske lidelser og autoimmune forstyrrelser